Calls Now Open
2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs
April 16, 2024
Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2024 class of Harrington Scholar-Innovators. The scholar awards will support breakthrough new treatments for heart disease, autoimmune disorders, cancer, infectious disease, inflammation, and rare diseases using small molecule...
Continue ReadingMarch 25, 2024
Nature Chemical Biology, published March 25, 2024 Continue Reading
December 13, 2023
The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading
December 08, 2023
Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading
December 05, 2023
New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading
September 29, 2023
Aleta hopes to initiate the registrational trial investigating ALETA-001 in B-cell malignancies in 2024/25. Continue Reading
April 14, 2023
Researchers have found a promising new method for delivering oxygen to tissues damaged by disease by coupling nitric oxide, which dilates blood vessels, with the oxygen carrying molecule hemoglobin to help people living with a number of diseases. Continue Reading
April 12, 2023
Harrington Scholar Dr. Khvorova and research team have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease. Continue Reading
February 23, 2023
UVA Health School of Medicine scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss. Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading